{"schema_version":"secwatch.filing_event.v1","accession":"0001815776-25-000025","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2025-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.841424+00:00","generated_at":"2026-05-23T14:52:05.860766+00:00","sec_items":["2.02","7.01","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"LENZ Therapeutics reports $194M cash as of March 31; holds Commercial Day for LNZ100 launch preparations","bullets":["Unaudited cash, cash equivalents and marketable securities approximately $194 million as of March 31, 2025.","Hosting Commercial Day on April 15, 2025, focusing on potential approval and launch of LNZ100.","Presentation includes commercialization strategies, supply chain readiness, and KOL perspectives.","Cash figure is preliminary and subject to completion of financial closing procedures.","No other financial results or guidance were provided in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001815776-25-000025","json":"https://secwatch.observer/filing/0001815776-25-000025.json","markdown":"https://secwatch.observer/filing/0001815776-25-000025.md","text":"https://secwatch.observer/filing/0001815776-25-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000025/0001815776-25-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000025/lenz-20250415.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T14:52:05.860766+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}